Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
SETDB1 encodes a histone methyltransferase which regulates histone methylation, gene silencing, and transcriptional repression. Additionally we are shipping SETDB1 Antibodies (117) and many more products for this protein.
Showing 5 out of 7 products:
SETDB1 is essential for the earliest events in lineage specification in the bovine blastocyst.
SETDB1 protein expression was significantly associated with poor survival and was related to TNM (show ODZ1 Proteins) stage.
SETDB1, a major histone H3K9 methyltransferase is monoubiquitinated at the evolutionarily conserved lysine-867 in its SET-Insertion domain. This ubiquitination is directly catalyzed by UBE2E family of E2 enzymes in an E3-independent manner while the conjugated-ubiquitin (Ub) is protected from active deubiquitination.
These results suggest that the ubiquitination of SETDB1 at lysine 867 controls the expression of its target gene by activating its H3K9 methyltransferase activity.
Authors observed several complementary mechanisms contributing to the upregulation of SETDB1 in HCC (show FAM126A Proteins) cells. Besides copy number gains at the SETDB1 gene locus at chromosome 1q21 enhanced SETDB1 transcription mediated by the transcription factor SP1 (show SP1 Proteins) could be detected.
BRCA1 and SETDB1 stand out as the most significant prognostic markers in this group of patients
These results suggest that SETDB1- mediated FosB (show FOSB Proteins) expression is a common molecular phenomenon, and might be a novel pathway responsible for the increase in cell proliferation that frequently occurs during anticancer drug therapy.
SETDB1 mutations are associated with malignant pleural mesotheliomas.
Upon HBV infection, cellular mechanisms involving SETDB1-mediated H3K9me3 and HP1 (show DEFA1 Proteins) induce silencing of HBV cccDNA transcription through modulation of chromatin structure.
The SETDB1 protein was closely associated with the prognosis of prostate cancer (PCa (show FLVCR1 Proteins)). Bioinformatics suggested that SETDB1 might promote PCa (show FLVCR1 Proteins) bone metastasis through the WNT (show WNT2 Proteins) pathway. In conclusion, SETDB1 might be associated with the development of bone metastases from PCa (show FLVCR1 Proteins)
results indicate that ATF7IP does not directly modulate SETDB1 catalytic activity, suggesting alternate roles, such as affecting cellular localization or mediating interaction with additional binding partners.
the SETDB1 repressor complex shields neuronal genomes from excess CTCF (show CTCF Proteins) genome organizer binding and is critically required for structural maintenance of the protocadherin locus topologically associated domain
The results identify Setdb1 as a newly discovered meiotic and embryonic competence factor safeguarding genome integrity at the onset of life.
study identifed ESET as first trimethylated H3K9 histone methyltransferase playing a crucial role in T cell development
Setdb1 maintains hematopoietic stem and progenitor cells by restricting the ectopic activation of nonhematopoietic genes.
SETDB1 maintains silencing of intracisternal A particle, but in the absence of DNMT1 (show DNMT1 Proteins), prolonged binding of NP95 (show UHRF1 Proteins) to hemimethylated DNA transiently disrupts SETDB1-dependent H3K9me3 deposition.
Deletion of Setdb1 led to enlarged Meckel's cartilage. Chondrocytes from the Meckel's cartilage of Setdb1 mutant showed increased in size.
Setdb1 is a maternal-effect gene that controls meiotic progression and is essential for early embryogenesis. Setdb1 is an important regulator of Cdc14b (show CDC14B Proteins).
The currently identified reciprocal action between SETDB1 and PRC2 reveals a novel mechanism underlying ES cell pluripotency and differentiation regulation.
regulates cancer cell growth via methylation of p53 (show TP53 Proteins)
This gene encodes a histone methyltransferase which regulates histone methylation, gene silencing, and transcriptional repression. This gene has been identified as a target for treatment in Huntington Disease, given that gene silencing and transcription dysfunction likely play a role in the disease pathogenesis. Alternatively spliced transcript variants of this gene have been described.
histone-lysine N-methyltransferase SETDB1
, SET domain, bifurcated 1
, histone-lysine N-methyltransferase SETDB1-like
, histone-lysine N-methyltransferase SETDB1-A
, ERG-associated protein with SET domain
, ERG-associated protein with a SET domain, ESET
, H3-K9-HMTase 4
, histone H3-K9 methyltransferase 4
, histone-lysine N-methyltransferase, H3lysine-9 specific 4
, lysine N-methyltransferase 1E
, tudor domain containing 21
, SET domain ERG-associated histone methyltransferase